- The denounced product has a manipulated health registration and third-party advertising permits.
- Furthermore, there are no technical studies that support its quality, safety and efficacy.
- Cofepris denounced that properties for the treatment of alterations caused by prostate enlargement are falsely attributed to it.
After a process of technical investigation, the Federal Commission for the Protection against Sanitary Risks (Cofepris) denounced an alleged herbal product marketed as Prostalif. The reason is because it does not have a health registry and should not be consumed because it represents a health hazard.
In this regard, this health authority detected that the product bears a false health registration. In addition, it was identified that on at least two occasions he presented to the public advertising permits that correspond to other products, which will lead to the corresponding legal actions.
Supposed properties that it has
In the health alert issued by the Evidence and Risk Management Commission (Cemar) of Cofepris is warned that the product is falsely attributed properties for the treatment of changes caused by enlarged prostate (benign prostatic hyperplasia), such as: sensation of incomplete emptying of urine, constant interruption of sleep to get up to urinate (nocturia) and urinary urgency, among others, as well as helping to reduce the size of the prostate.
The authority does not have evidence to guarantee that the product meets the technical studies to treat these conditions, so its consumption represents a health risk and a deception to the population.
Cofepris also has no evidence of the content of the raw materials (ingredients) and the manufacturing process of said product. The National Reference Laboratory performs the analytical investigation to detect the true compounds of the deception product. In addition, it is unknown if it has technical and clinical studies that guarantee its quality, safety and efficacy, so it should not be consumed by people, since it can cause serious health effects.
It is alerted that this product is marketed in electronic media and on various internet sales platforms. It is also promoted in the media as herbal medicine.
In this regard, Cofepris, through the Sanitary Operation Commission (COS), sent a letter to various media outlets and supermarket chains to publicize the alert corresponding to this product, and prohibit their advertising and/or commercialization.
Cofepris recommendations
- Do not purchase or recommend the use or consumption of the Prostalif product, as well as any other product that does not comply with current health regulations.
- Do not combine the use of these products with medications, since their exact ingredients and concentration are unknown, which may cause a secondary reaction or damage to health.
- If you have any condition, you should see a health professional.
- Do not replace the medications prescribed by your treating physician with some deceitful product that alludes to eliminating diseases or reducing symptoms.
- If you find the aforementioned product for sale or identify the promotion, it is pertinent to file the corresponding health complaint through the Cofepris website.
Finally, it is reported that because these are products that do not comply with current health legislation, they should not be marketed by any means or distributed by parcel services, national and/or international courier; nor be advertised on websites or on social network pages or of any kind within national territory. Otherwise, whoever violates this provision will be subject to the sanctions stipulated in current legislation.
This regulatory authority continues to carry out health surveillance actions to prevent products, companies or establishments from failing to comply with health legislation and representing a risk to the health of the population.
Also read:
Cofepris is modernized: Advertising notice process can now be done online
Cofepris publishes a list of 7 counterfeit and illegal drugs: Rivotril, Buscapina and more
This is the dirtiest beach in Mexico according to Cofepris: It has excess enterococci